CXCL12 and neoplasm: Zboralski et al.123 generated heterotypic 3D organoids with cells from different tumor types (e.g., colon and brain cancer) and cancer-associated fibroblasts to evaluate the effect of CXCL-12 inhibition on the efficacy of T-cell PD-1 blockade.